Search results for "digestive"

showing 10 items of 2631 documents

Clinical Trial Results of Peginterferons in Combination with Ribavirin

2003

Of the large number of patients chronically infected with hepatitis C virus (HCV), only about one third have progressive liver disease, and will eventually develop cirrhosis and hepatocellular carcinoma. These are the patients for whom effective antiviral treatment is most needed. Therapy is currently recommended for patients with chronic hepatitis C who have abnormal alanine aminotransferase (ALT) levels, detectable hepatitis C virus ribonucleic acid (HCV RNA) in the blood, and significant necroinflammatory changes and/or fibrosis on liver biopsy. The current gold standard in terms of treatment efficacy is the combination of peginterferon (PEG-IFN) and ribavirin. The overall sustained viro…

medicine.medical_specialtyCirrhosisHepatitis C virusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyDrug Administration SchedulePolyethylene Glycolsantiviral agentchemistry.chemical_compoundPharmacotherapyInternal medicineRibavirinmedicineHumansClinical Trials as TopicDrug CarriersHepatologymedicine.diagnostic_testbusiness.industryRibavirinInterferon-alphavirus diseasesHepatitis CHepatitis C Chronicmedicine.diseaseRecombinant Proteinsdigestive system diseasesTreatment OutcomechemistryLiver biopsyHepatocellular carcinomaImmunologyclinical trials hepatitis CDrug Therapy CombinationbusinessViral loadSeminars in Liver Disease
researchProduct

Non-alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches

2013

Non-alcoholic fatty liver disease (NAFLD) refers to a disease spectrum, ranging from mere hepatic steatosis to hepatic necroinflammation (NASH, non-alcoholic steatohepatitis). NASH often leads to fibrosis, which can progress to cirrhosis with a high risk of liver failure and hepatocellular carcinoma. The course of NAFLD is highly variable, and only a minority of patients (2-3%) progress to end-stage liver disease. However, due to a dramatic increase of the risk factors for NAFLD, that is obesity and insulin resistance/type 2 diabetes, that affect 15-30% and 7-15% of subjects, in most industrialized countries, respectively, NAFLD has become the most frequent liver disease and is even conside…

medicine.medical_specialtyCirrhosisHepatologybusiness.industryFatty liverGastroenterologynutritional and metabolic diseasesmedicine.diseaseBioinformaticsdigestive systemdigestive system diseasesLiver diseaseEndocrinologyInsulin resistanceLipotoxicityInternal medicinemedicineSteatosisSteatohepatitisMetabolic syndromebusinessJournal of Gastroenterology and Hepatology
researchProduct

Gastroesophageal Reflux and Bleeding Esophageal Varices

1979

The incidence of gastroesophageal reflux was evaluated with the use of a pH probe in 12 patients with cirrhosis and recent variceal hemorrhage and in 15 healthy control subjects. Short episodes of reflux occurred in 42% of the patients and in 47% of the controls. During an observation period of 1 hr, the cumulative duration of reflux was similar in patients (2.5 ± 1.3 min) and controls (3.1 ± 1.4 min). Mean lower esophageal sphincter pressures were normal in both groups but did not show a significant correlation with the duration of reflux. These data support previous observations that gastroesophageal reflux does not appear to be a contributing factor in the development of variceal hemorrh…

medicine.medical_specialtyCirrhosisHepatologybusiness.industryIncidence (epidemiology)digestive oral and skin physiologyGastroenterologyRefluxVariceal hemorrhagemedicine.diseaseGastroenterologydigestive system diseasesInternal medicineHealthy controlmedicineBleeding esophageal varicesEsophageal sphincterIn patientbusinessGastroenterology
researchProduct

Frailty and Sarcopenia in Acute‐on‐Chronic Liver Failure

2021

In patients with cirrhosis, sarcopenia is a critical reduction in skeletal muscle mass and frailty represents a status of global physical dysfunction caused by under nutrition, muscle wasting, and functional impairment. Both are prevalent conditions in liver transplant candidates and have shown to be independent predictors of adverse outcome. Evidence supports their incorporation into clinical practice both as a prognostic factor guiding clinical decision making and as a tool to identify candidates for physical and nutritional interventions. The wide heterogeneity of instruments used for sarcopenia and frailty measurement, the absence of a single suitable instrument for sarcopenia and frail…

medicine.medical_specialtyCirrhosisHepatologybusiness.industryRC799-869ReviewDiseases of the digestive system. Gastroenterologymedicine.diseaseFrailty assessmentUnder nutritionTransplantationSarcopeniamedicineAcute on chronic liver failureIn patientmedicine.symptomIntensive care medicinebusinessWastingHepatology Communications
researchProduct

Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice.

2020

Nonalcoholic fatty liver disease (NAFLD) is a clinical condition that encompasses various forms of liver damage not caused by chronic alcohol consumption. In the absence of other etiologies, it ranges from ste- atosis to nonalcoholic steatohepatitis and cirrhosis. The prevalence of NAFLD has considerably increased over the last years owing to the current lifestyle (unhealthy diet and sedentarism). Besides, it is associated with metabolic risk factors such as obesity, arterial hypertension, dyslipidemia, and type 2 diabetes. Given the poor prognosis of patients with advanced NAFLD, a practical therapeutic approach is necessary to halt its natural history. However, no licensed drugs have been…

medicine.medical_specialtyCirrhosisbusiness.industrynutritional and metabolic diseasesDiseaseType 2 diabetesComorbiditymedicine.diseaseObesitydigestive system diseasesArterial hypertension Dyslipidemia Nonalcoholic fatty liver disease Type 2 diabetes Comorbidity Humans Obesity Weight Loss Diabetes Mellitus Type 2 Non-alcoholic Fatty Liver DiseaseDiabetes Mellitus Type 2Weight lossNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseaseWeight LossInternal MedicinemedicineHumansObesitymedicine.symptomSteatosisbusinessDyslipidemiaPolish archives of internal medicine
researchProduct

Longterm Survival After Liver Transplantation for Autoimmune Hepatitis : Results From the European Liver Transplant Registry

2020

The aim of this study was to analyze longterm patient and graft survival after liver transplantation for autoimmune hepatitis (AIH-LT) from the prospective multicenter European Liver Transplant Registry. Patient and liver graft survival between 1998 and 2017 were analyzed. Patients after AIH-LT (n = 2515) were compared with patients receiving LT for primary biliary cholangitis (PBC-LT; n = 3733), primary sclerosing cholangitis (PSC-LT; n = 5155), and alcohol-related cirrhosis (AC-LT; n = 19,567). After AIH-LT, patient survival was 79.4%, 70.8%, and 60.3% and graft survival was 73.2%, 63.4%, and 50.9% after 5, 10, and 15 years of follow-up. Overall patient survival was similar to patients af…

medicine.medical_specialtyCirrhosismedicine.medical_treatmentCholangitis SclerosingMedizinAutoimmune hepatitis030230 surgeryLiver transplantationGastroenterologyPrimary sclerosing cholangitis03 medical and health sciences0302 clinical medicineInternal medicinemedicineLiving DonorsHumansProspective StudiesRegistriesTransplantationHepatologybusiness.industryLiver Cirrhosis BiliaryHazard ratioPatient survivalmedicine.diseasedigestive system diseasesLiver TransplantationHepatitis AutoimmuneIncreased risk030211 gastroenterology & hepatologySurgeryGraft survivalbusiness
researchProduct

A New Score Unveils a High Prevalence of Mild Cognitive Impairment in Patients with Nonalcoholic Fatty Liver Disease

2021

Patients with nonalcoholic fatty liver disease (NAFLD) may show mild cognitive impairment (MCI). The neurological functions affected remain unclear. The aims were to: (1) Characterize the neuropsychological alterations in NAFLD patients; (2) assess the prevalence of impairment of neurological functions evaluated; (3) develop a new score for sensitive and rapid MCI detection in NAFLD; (4) assess differences in MCI features between patients with nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH); and (5) compare neuropsychological alterations in NAFLD patients with cirrhotic patients with MCI. Fifty-nine NAFLD patients and 53 controls performed psychometric tests assessin…

medicine.medical_specialtyCirrhosisneurological impairmentpsychometric scoreGastroenterologybehavioral disciplines and activitiesdigestive systemArticle03 medical and health sciences0302 clinical medicineInternal medicineNAFLDNonalcoholic fatty liver diseasemedicineMemory spanHepatic encephalopathyPsychomotor learningbusiness.industryFatty liverRNeuropsychologyNASHnutritional and metabolic diseasesGeneral Medicinemedicine.diseasepsychometric score; NAFLD; NAFL; NASH; neurological impairmentdigestive system diseasesNAFLMedicine030211 gastroenterology & hepatologybusiness030217 neurology & neurosurgeryStroop effectJournal of Clinical Medicine
researchProduct

Computed Tomography of HCC

2016

Contrast-enhanced CT allows an accurate noninvasive diagnosis of Hepatocellular Carcinoma (HCC) nodules, and assessment of hepatic vascular anatomy and patency. The use of state-of-the-art equipment and of a tailored protocol is crucial. CT results help to detect and stage HCC, select the best treatment option, and evaluate response to therapy. In this chapter, the CT protocol for the cirrhotic liver, the CT features of HCC before and after treatment and of portal vein thrombosis will be described.

medicine.medical_specialtyCirrhotic liverResponse to therapymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentComputed tomographymedicine.diseasedigestive system diseasesPortal vein thrombosisHepatocellular carcinomamedicineRadiologyPercutaneous ethanol injectionStage (cooking)businessAfter treatment
researchProduct

Aloe vera: not always so beneficial in patients with chronic liver disease

2013

medicine.medical_specialtyCirrosis hepaticabiologybusiness.industryGastroenterologyMEDLINEGeneral Medicinebiology.organism_classificationChronic liver diseasemedicine.diseaseGastroenterologyAloe veraChronic diseaseInternal medicinemedicineIn patientlcsh:Diseases of the digestive system. Gastroenterologylcsh:RC799-869businessRevista Espanola de Enfermedades Digestivas
researchProduct

Rhein stimulates active chloride secretion in the short-circuited rat colonic mucosa.

1988

In a short-circuited mucosa-submucosa preparation of the rat descending colon with preserved Meissner's plexus mounted as an everted sac rhein transiently increased the potential difference and short-circuit current (Isc) when administered serosally and mucosally, but serosal application was more effective. Maximal effects were obtained at rhein concentrations of 1.6 X 10(-4) and 3 X 10(-4) mol/l. Net chloride absorption was decreased. Indomethacin (5 X 10(-6) mol/l) did not inhibit the increase of Isc, but omission of calcium from the serosal side as well as tetrodoxin (2 X 10(-7) mol/l) decreased it by 50 and 60%. Mechanical removal of Meissner's plexus partly blocked the effect of rhein,…

medicine.medical_specialtyColonIndomethacinAnthraquinonesTetrodotoxindigestive systemDescending colonMembrane PotentialsChloridesInternal medicinemedicineAnimalsChloride secretionIntestinal MucosaPharmacologyPlexusDose-Response Relationship DrugChemistryCatharticsdigestive oral and skin physiologyRats Inbred StrainsGeneral MedicineSubmucous Plexusdigestive system diseasesRatsIntestinal secretionColonic mucosaEndocrinologymedicine.anatomical_structurePotential differenceCalciumFemalePharmacology
researchProduct